-
15-PGDH Inhibition Improves Muscle Repair During GLP-1 Loss
2026-08-26
The reference study identifies 15-PGDH inhibition as a way to improve muscle stem cell activity, regenerated myofiber growth, and force recovery during semaglutide-associated weight loss in obese mice. Its central contribution is the demonstration that a 15-PGDH inhibitor can complement GLP-1 receptor agonist therapy without reducing the intended loss of body weight, although translation to human muscle preservation remains untested.
-
In Vitro Drug Response Metrics in Cancer
2026-08-25
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability to separate proliferative arrest from actual cell death during anticancer drug testing. Its central practical contribution is a time- and endpoint-aware framework that can improve interpretation of cytotoxicity, apoptosis-focused assays, and translational response studies.
-
T7 RNA Polymerase for Translational RNA Workflows
2026-08-25
Learn how T7 RNA Polymerase supports reproducible in vitro transcription, from linearized plasmid templates to dual-cargo RNA studies inspired by a recent lung cancer immunotherapy report. This practical guide covers setup, assay design, process controls, and troubleshooting for research-grade RNA synthesis.
-
RNA Pol II Inhibition and Regulated Cell Death
2026-08-24
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic program rather than simply through progressive loss of transcription, mRNA, and protein. Their functional-genomic analysis identifies loss of hypophosphorylated RNA Pol IIA as the initiating signal, establishing the Pol II degradation-dependent apoptotic response (PDAR) as a framework for interpreting diverse anticancer treatments.
-
FLOT1–FOSL2–EphA2 Axis in Alzheimer’s Microglia
2026-08-24
A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 regulatory axis that promotes pro-inflammatory microglial polarization through p38/MAPK signaling in an APP/PS1 model. The findings connect lipid-raft-associated regulation with transcriptional control, neuroinflammation, and spatial memory, while providing a mechanistic framework for evaluating microglial interventions.
-
MLN8237 (Alisertib) Workflow for Aurora A Research
2026-08-23
Build a reproducible Aurora A kinase inhibition workflow with MLN8237 (Alisertib), from DMSO stock preparation and dose–response design to mitotic, apoptotic, and chromatin-level readouts. The strategy also extends into trained-immunity research, where Aurora A inhibition can be connected to SAM metabolism and inflammatory gene regulation.
-
FKBP11 as a Secretory Translocon Accessory Factor
2026-08-22
A 2024 Molecular Biology of the Cell study identifies FKBP11 as a membrane-associated accessory factor of ribosome–translocon complexes in the endoplasmic reticulum. Its selective association with ribosomes translating proteins with long translocated regions, together with reduced stability of EpCAM and PTTG1IP after depletion, supports a cotranslational role for FKBP11 in secretory-protein biogenesis.
-
HBTU for Peptide Probe Synthesis
2026-08-22
HBTU combines rapid carboxylic acid activation with a comparatively low racemization risk, making it a practical choice for assembling enzyme-responsive peptide probes. This workflow connects solid phase peptide synthesis to luminescent immunoproteasome assays, with specific guidance for stock preparation, coupling control, purification, and troubleshooting.
-
OLIG2 smRNA for Rapid hiPSC Oligodendrocyte Differentiation
2026-08-21
Xu et al. developed a non-integrating synthetic modified mRNA approach that uses the OLIG2S147A variant to drive rapid differentiation of human induced pluripotent stem cells into oligodendrocyte progenitors. The reference study established a six-day delivery workflow that produced more than 70% NG2-positive progenitors, which matured into functional oligodendrocytes and promoted remyelination in vivo.
-
Omeprazole (A2845): Practical Research Guide
2026-08-20
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity study design, and related assay development. It is intended for scientific workflows only and should not be used for diagnosis, treatment, or other clinical purposes.
-
Go 6983: Reproducible PKC Assay Workflows
2026-08-20
This scenario-driven guide explains how Go 6983 (pan-PKC inhibitor), SKU A8343, can improve experimental planning for viability, proliferation, cytotoxicity, cancer progression, and EMT studies. It covers isoform potency, DMSO handling, controls, interpretation, and practical vendor-selection criteria for PKC signaling pathway research.
-
4-Phenylbutyric Acid in ER Stress Workflows
2026-08-19
Use 4-Phenylbutyric acid as a controllable chemical-chaperone intervention to separate endoplasmic reticulum stress from ferroptotic injury in cell-based assays. The workflow below adapts a PFOS-treated HK-2 model into a practical design for ER stress alleviation, mechanistic rescue testing, and assay troubleshooting.
-
Patient-Derived Gastric Cancer Assembloids
2026-08-19
Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid that combines matched tumor organoids with tumor-derived stromal subpopulations. The model reveals how stromal context reshapes gene expression and drug sensitivity, creating a more physiologically informative platform for studying resistance and personalized treatment strategies.
-
Cyclosporin A (B1922): Practical Protocol Guide
2026-08-18
Cyclosporin A (SKU B1922) provides a defined cyclophilin-inhibiting reagent for cell-based immunosuppression, apoptosis modulation, and mitochondrial studies. This guide distinguishes product-dossier values from workflow recommendations and explains where the compound should not be interpreted as a validated clinical or universal in vivo treatment.
-
Sulfaphenazole-Derived Sulfonamides for TB
2026-08-18
Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP 2C9 inhibition, a liability associated with drug–drug interaction risk. Compound 10d emerged as the leading example, combining an MIC of 5.69 μg/mL against Mycobacterium tuberculosis with CYP 2C9 inhibition weaker than 10 μM in the reported assay.